Press Releases

Date	Title
March 5, 2020	Outlook Therapeutics Announces LYTENAVA™ (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If Approved Outlook Therapeutics intends to market ONS-5010 as LYTENAVA ™ (bevacizumab-vikg), if approved. LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for retinal indications, is currently in two registration clinical trials (NORSE 1 and NORSE 2) to treat wet
February 26, 2020	Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market CRANBURY, N.J. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has
February 24, 2020	Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market CRANBURY, N.J. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has
February 14, 2020	Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020 First clinical trial results from the Phase 3 development program for ONS-5010 expected in six months CRANBURY, N.J. , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA
February 4, 2020	Outlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference CRANBURY, N.J. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA -approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it is
January 28, 2020	Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010 CRANBURY, N.J. , Jan. 28, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA -approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has
December 26, 2019	Outlook Therapeutics Announces Completion of Warrant Restructuring CRANBURY, N.J. , Dec. 26, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA -approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has
December 23, 2019	Outlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate Transactions CRANBURY, N.J. , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA -approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has
December 19, 2019	Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2019 Topline results from the NORSE 1 study of ONS-5010 expected to be announced in the third quarter of calendar 2020 Enrollment in the NORSE 2 study underway SPA agreement reached with FDA for NORSE 4, 5 and 6 studies CRANBURY, N.J. , Dec. 19, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.
December 3, 2019	Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010 ONS-5010, an investigational ophthalmic formulation of bevacizumab for retinal indications, is currently in two clinical trials to treat wet age-related macular degeneration (wet AMD – NORSE 1 and 2). SPAs for clinical trial protocols for NORSE 4 for branch retinal vein occlusion (“BRVO”) and